Guardian Pharmacy Q4 Revenue Up 18%, Adjusted EPS 37¢ Beats; 2026 EBITDA Raised
Guardian Pharmacy reported Q4 revenue of $397.6M, up 18% with 13% organic growth, and net income of $20.9M (33¢ EPS) alongside adjusted EPS of $0.37. It added $60M cash, exited at a $110M EBITDA run rate and raised 2026 EBITDA guidance despite a 90-bp margin drag.
1. Q4 Financial Results
Guardian Pharmacy posted Q4 revenue of $397.6 million, marking 18% growth from last year driven by 13% organic expansion and acquisition contributions. Net income was $20.9 million, or $0.33 per share, with adjusted earnings of $0.37 per share.
2. Margin Impact and Operational Factors
Integration of recent acquisitions dampened operating margins by roughly 90 basis points, while industry shifts—such as branded inhaler pricing challenges and consolidation at the facility level—added complexity. Headwinds from changes in government programs have affected long-term care pharmacy reimbursement dynamics.
3. Cash Increase and 2026 Outlook
The company boosted its cash balance by approximately $60 million and reported a $110 million EBITDA run rate exiting 2025. It raised its 2026 adjusted EBITDA guidance and projected full-year revenue between $1.40 billion and $1.42 billion, underscoring financial flexibility.